Metformin in obesity, cancer and aging: addressing controversies

Area of Science:

• Pharmacology and Therapeutics
• Gerontology
• Oncology

Background:

• Metformin, an oral anti-diabetic medication, is gaining attention for potential applications beyond diabetes management.
• Emerging research suggests metformin may play a role in cancer prevention, obesity treatment, and promoting a healthy lifespan.
• However, conflicting results across studies necessitate a closer examination of influencing factors.

Purpose of the Study:

• To explore the reasons behind discrepancies in research findings regarding metformin's effects on cancer, obesity, and aging.
• To differentiate between methodological variations and inherent individual differences in patient response to metformin.
• To critically evaluate the current evidence on metformin's potential anti-aging properties.

Main Methods:

• Review and analysis of existing randomized clinical trials and experimental studies on metformin.
• Investigation of factors contributing to study variability, including control group selection, gender, age, and pharmacogenetics.
• Discussion of the current state of research on metformin's anti-aging effects.

Main Results:

• Discrepancies in metformin's effects on cancer and obesity may be attributed to limited randomized trials, varied control groups, and demographic/pharmacogenetic factors.
• Studies on metformin's anti-aging potential are still in the experimental phase and yield ambiguous results.
• The observed variations in study outcomes could be due to methodological issues or intrinsic differences in individual drug responsiveness.

Conclusions:

• Methodological inconsistencies and individual patient variability are key factors influencing metformin's observed effects.
• Further rigorous research is needed to clarify metformin's efficacy in cancer, obesity, and longevity.
• Understanding individual responses to metformin is crucial for optimizing its therapeutic applications.